☆ 4.2 Article

NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives

CANCER GENETICS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pharmacology & Pharmacy

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers

Tingting Jiang et al.

Summary: TRKA, TRKB, and TRKC are important members of the cell surface receptor tyrosine kinase family, regulating cell proliferation, differentiation, and apoptosis. NTRK gene fusions act as oncogenic drivers for a variety of tumors, making TRK inhibitors promising targets for anti-tumor therapy.

ACTA PHARMACEUTICA SINICA B (2021)

添加到收藏夹

Review Cell Biology

Modeling the developmental origins of pediatric cancer to improve patient outcomes

James F. Amatruda

Summary: Multimodal approaches are crucial in treating pediatric cancer, but may result in lifelong health issues for survivors. Current therapies, though showing progress, still require further research on how genetic changes drive cancer transformation.

DISEASE MODELS & MECHANISMS (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Multikinase inhibitors in thyroid cancer: timing of targeted therapy

Matti L. Gild et al.

Summary: This review summarizes the evidence from clinical trials on the efficacy of tyrosine kinase inhibitors in treating thyroid cancer. It also discusses the experience with these drugs in clinical practice and factors that can help clinicians decide when to start or continue tyrosine kinase inhibitor therapy.

NATURE REVIEWS ENDOCRINOLOGY (2021)

添加到收藏夹

Article Genetics & Heredity

Comprehensive tumor molecular profile analysis in clinical practice

Mustafa Ozdogan et al.

Summary: Tumor molecular profile analysis using Next Generation Sequencing technology is widely applied in clinical practice, enabling the detection of predictive biomarkers for targeted treatment. This study analyzed 610 cancer patients and found actionable alterations in 77.87% of them, with 54.75% receiving information related to on-label or off-label treatment and 21.31% having variants suitable for clinical trial inclusion. Additionally, simultaneous analysis for targeted therapy and immunotherapy biomarkers could provide actionable information for the majority of patients.

BMC MEDICAL GENOMICS (2021)

添加到收藏夹

Article Oncology

Histology-based molecular profiling improves mutation detection for advanced thyroid cancer

Markus Eszlinger et al.

Summary: This study comprehensively characterized advanced, metastatic, radioiodine-resistant thyroid carcinomas at the molecular level and found a significant association between histologic and molecular heterogeneity, providing important insights for guiding precision medicine approaches.

GENES CHROMOSOMES & CANCER (2021)

添加到收藏夹

Article Multidisciplinary Sciences

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma

Marjorie G. Zauderer

Summary: Researchers have shed light on the genomic complexities of MPM and highlighted the importance of combining drug development with predictive biomarkers.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Oncology

Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges

Erika Durinikova et al.

Summary: Colorectal cancer is a complex and heterogeneous disease with poor prognosis, but utilizing effective preclinical models can provide better personalized treatment recommendations for patients. Researchers emphasize that novel therapies should be tested initially on reliable models to avoid overtreatment and unnecessary toxicity.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer

Alvida Qvick et al.

Summary: This study investigates the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer, as well as characterizing liquid biopsy variants and correlating mutational load with clinical data. The results show significantly more variants detected in lung cancer patients compared to controls, and the number of variants in plasma is associated with prognosis in lung cancer.

MOLECULAR MEDICINE (2021)

添加到收藏夹

Letter Oncology

Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult

Julie Boyer et al.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion

Daniel J. Shepherd et al.

Summary: This article reports a case of a 26-year-old man with NTRK2-rearranged glioblastoma who showed a temporary response to the NTRK inhibitor larotrectinib. Rebiopsy after disease progression revealed the emergence of a PDGFRA-amplified subclone, highlighting the potential efficacy of targeted therapy and the implications of molecular heterogeneity in glioblastoma.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion

Lindsey Mortensen et al.

Summary: Enhanced understanding of the molecular events underlying oncogenesis has led to the development of tumoragnostic treatment strategies that target a tumor's genomic profile regardless of its anatomic site of origin. One classic example is the ETV6-NTRK3 gene fusion, which activates the TRK protein, leading to increased cell survival, growth, and proliferation.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer

Jiali Xu et al.

Summary: A targeted DNA profiling study of Chinese patients with head and neck cancers revealed a higher prevalence of NTRK genetic aberrations in this population, suggesting the need for further investigation into the efficacy of NTRK inhibitors. The study also identified associations between NTRK aberrations, TP53 and LRP1B mutations, and tumor mutation burden (TMB), indicating potential markers for immunotherapy.

ORAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

Alfredo Tartarone et al.

Summary: Targeted therapies against oncogenic drivers have significantly improved the survival of NSCLC patients, and genetic testing is essential for diagnosis and treatment. Various novel druggable oncogenic drivers have been identified for potential targeted therapy.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake

Young Ah Lee et al.

Summary: This study investigated the molecular characteristics of pediatric papillary thyroid cancer (PTC) and identified different genetic drivers, including fusion oncogenes and point mutations. For patients with fusion oncogene PTC, fusion-directed therapy may lead to dramatic tumor responses.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Review Oncology

From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm

Jacob J. Adashek et al.

Summary: Precision medicine has revolutionized the treatment of lethal cancers through next-generation sequencing and targeted drug deployment, highlighting the need for personalized treatments with drug combinations and customization. Real-world data and registry trials are expected to further drive the evolution of oncology.

TRENDS IN CANCER (2021)

添加到收藏夹

Article Pediatrics

Bilateral papillary thyroid cancer in children: Risk factors and frequency of postoperative diagnosis

Heron Baumgarten et al.

JOURNAL OF PEDIATRIC SURGERY (2020)

添加到收藏夹

Article Oncology

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

Robert C. Doebele et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Review Genetics & Heredity

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues

Massimo Santoro et al.

GENES (2020)

添加到收藏夹

Article Oncology

US Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

Marie Wong et al.

NATURE MEDICINE (2020)

添加到收藏夹

Letter Medicine, General & Internal

Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer

Lionel Groussin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Biology

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Romel Somwar et al.

COMMUNICATIONS BIOLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Entrectinib: First Global Approval

Zaina T. Al-Salama et al.

DRUGS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

Emiliano Cocco et al.

NATURE MEDICINE (2019)

添加到收藏夹

Review Oncology

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

A. Amatu et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?

Cinta Hierro et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Larotrectinib: First Global Approval

Lesley J. Scott

DRUGS (2019)

添加到收藏夹

Article Oncology

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

Theodore W. Laetsch et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions

Sogol Mostoufi-Moab et al.

THYROID (2018)

添加到收藏夹

Article

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Bruce W. Konicek et al.

Oncotarget (2018)

添加到收藏夹

Article Oncology

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations

Alexander Drilon et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Review Oncology

NTRK fusion-positive cancers and TRK inhibitor therapy

Emiliano Cocco et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas

Jie Zhang et al.

JOURNAL OF NEURO-ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

Mariangela Russo et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine

James Nagarajah et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

添加到收藏夹

Article Oncology

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance

Susan Breslin et al.

ONCOTARGET (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

Gary L. Francis et al.

THYROID (2015)

添加到收藏夹

Article Oncology

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

Robert C. Doebele et al.

CANCER DISCOVERY (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Nishant Agrawal et al.

CELL (2014)

添加到收藏夹

Review Endocrinology & Metabolism

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets

Christine Spitzweg et al.

LANCET DIABETES & ENDOCRINOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

Alan L. Ho et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

Emmanuelle Huillard et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

添加到收藏夹

Article Medicine, Research & Experimental

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

Debyani Chakravarty et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

添加到收藏夹

Article Oncology

Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

Joshua D. Schiffman et al.

CANCER RESEARCH (2010)

添加到收藏夹

Article Oncology

Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice

Monica Fedele et al.

ENDOCRINE-RELATED CANCER (2009)

添加到收藏夹

Article Oncology

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

R Meuwissen et al.

CANCER CELL (2003)

添加到收藏夹

Article Biochemistry & Molecular Biology

The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium

JP Russell et al.

ONCOGENE (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.